Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
STING Activation via Cyclic Dinucleotide: Exploring A Therapeutic Modality for Treating Soft Tissue Sarcoma
FY 2019-20
Summary
"Soft tissue sarcomas (STS) are rare cancers derived from the connective tissues. The most common STS in adults is Undifferentiated Pleomorphic Sarcoma (UPS) which are highly aggressive tumours. Current treatment options for UPS patients include morbid tumour resections and amputations, chemotherapy, and radiation. Immunotherapy is an emerging cancer therapy that has been successfully used to treat melanoma and numerous carcinomas. However, immunotherapies have not been effective against sarcomas due to the lack of immune cells found within UPS tumours. Novel interventions that are capable of recruiting activated immune cells into the tumour microenvironment are desperately needed to effectively combat sarcoma. We are targeting this strategy by using small molecule activator of the STING receptor (STimulator of INterferon Genes). In pilot experiments, a single dose of the murine STING agonist DMXAA yielded full regression in 60% of treated UPS bearing mice. These encouraging results motivated our laboratory to evaluate STING agonists capable of activating both human and murine STING for UPS treatment. To accomplish this goal, we will be assessing the effectiveness of the human and murine STING agonist ML RR S2-CDA (CDA) which has been successfully used as an immunotherapy in other cancer models. To evaluate CDA's therapeutic potential in our mouse model of UPS, we will be optimizing CDA dosing strategies, combining CDA with current checkpoint inhibitor therapies to determine if it will sensitize tumours to the therapy, and finally, we will quantify markers of immune cell infiltration in tumours following CDA therapy. Investigating STING activation as an immunotherapeutic strategy holds the potential to dramatically improve treatment options for UPS patients. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428843
Name
Hildebrand Karys M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
STING Activation via Cyclic Dinucleotide: Exploring A Therapeutic Modality for Treating Soft Tissue Sarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
5; 6; Checkpoint Inhibitors; Cyclic Dinucleotides (Cdn); Dimethylxanthenone-4actetic Acid (Dmxaa); Immunotherapy; Soft Tissue Sarcoma; Stimulator Of Interferon Genes Pathway (Sting)
Abstract
"Soft tissue sarcomas (STS) are rare cancers derived from the connective tissues. The most common STS in adults is Undifferentiated Pleomorphic Sarcoma (UPS) which are highly aggressive tumours. Current treatment options for UPS patients include morbid tumour resections and amputations, chemotherapy, and radiation. Immunotherapy is an emerging cancer therapy that has been successfully used to treat melanoma and numerous carcinomas. However, immunotherapies have not been effective against sarcomas due to the lack of immune cells found within UPS tumours. Novel interventions that are capable of recruiting activated immune cells into the tumour microenvironment are desperately needed to effectively combat sarcoma. We are targeting this strategy by using small molecule activator of the STING receptor (STimulator of INterferon Genes). In pilot experiments, a single dose of the murine STING agonist DMXAA yielded full regression in 60% of treated UPS bearing mice. These encouraging results motivated our laboratory to evaluate STING agonists capable of activating both human and murine STING for UPS treatment. To accomplish this goal, we will be assessing the effectiveness of the human and murine STING agonist ML RR S2-CDA (CDA) which has been successfully used as an immunotherapy in other cancer models. To evaluate CDA's therapeutic potential in our mouse model of UPS, we will be optimizing CDA dosing strategies, combining CDA with current checkpoint inhibitor therapies to determine if it will sensitize tumours to the therapy, and finally, we will quantify markers of immune cell infiltration in tumours following CDA therapy. Investigating STING activation as an immunotherapeutic strategy holds the potential to dramatically improve treatment options for UPS patients. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hildebrand, Karys M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~